In the face of mounting nationwide lawsuits and continuing alarming testing data, the United States Food and Drug Administration (FDA) has finally announced it is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately. As a result of this immediate market withdrawal request, ranitidine products (commonly known by the brand name Zantac) will not be available for new or existing prescriptions or OTC use in the U.S.
The FDA is also advising consumers taking OTC ranitidine to stop taking any tablets or liquid they currently have, and seek other drugs approved for the same or similar uses as ranitidine that do not carry the same cancer risks.
We have previously discussed early independent laboratory testing that showed high levels of the harmful compound N-Nitrosodimethylamine (NDMA) in ranitidine medications. Initially, we reported that the FDA had a relatively tepid response to these very troubling findings, suggesting that some of the high NDMA levels may have merely been produced by the testing methods employed (basically saying that the samples were subject to high temperatures during testing that may have caused the ranitidine to break down into NDMA).
With this latest action, the FDA now asserts that:
New FDA testing and evaluation prompted by information from third-party laboratories confirmed that NDMA levels increase in ranitidine even under normal storage conditions, and NDMA has been found to increase significantly in samples stored at higher temperatures, including temperatures the product may be exposed to during distribution and handling by consumers. The testing also showed that the older a ranitidine product is, or the longer the length of time since it was manufactured, the greater the level of NDMA.
The FDA also stated that “sustained higher levels of exposure may increase the risk of cancer in humans.” This forms one of the many bases of the Zantac lawsuits that continue to be filed across the nation. Previously, we discussed the best way to determine whether you may have a claim encompassed within those lawsuits.
You are already reading our blog, but feel free to look us up on our website at, check us out on Facebook and Twitter, or just call us anytime, free of charge, at 609.895.7369. We are not like many of the marketing companies you have seen on television. Established in 1933, we are a firm of over 100 attorneys, including experienced trial attorneys who you can meet and talk to about your case.
Stark & Stark Attorneys Recognized as New Jersey “Super Lawyers” and “Rising Stars” in 2026
Stark & Stark is pleased to announce that 15 of its attorneys have been selected for inclusion in the list of 2026 New Jersey Super Lawyers,...Bruce Stern, Esq. Secures $1,000,000 Settlement in Motor Vehicle Collision Case
Bruce Stern, Esq. recently secured a $1,000,000 settlement in a motor vehicle collision case.* “This case highlights how quickly things can go...Deborah Dunn, Esq. Elected to Board of Directors for Angel Flight East
Stark & Stark is pleased to announce that Deborah Dunn, Esq., Shareholder and Civil Trial Attorney, has been elected to the Board of Directors...Michael Jordan, Esq. Joins the Board of the Lawrence Township Community Foundation
It is our pleasure to announce that Michael Jordan, Esq. has joined the board of the Lawrence Township Community Foundation, an organization...Joseph Lemkin, Esq. Named to ROI-NJ Influencers: Power List 2026 – Law
Stark & Stark is proud to share that Joseph Lemkin, Esq., Shareholder, has been named to the 2026 Influencers: Power List in the Law category...Joseph Cullen, Esq. and Nicole Durso, Esq. Secure $2,000,000 Settlement in Personal Injury Matter
Joseph Cullen, Esq. and Nicole Durso, Esq. recently secured a $2,000,000 settlement in a personal injury matter involving a pedestrian who was struck...